Angioscopic Assessment of Peri-Stent Contrast Staining Following Drug-Eluting Stent Implantation

Ishihara, Takayuki; Awata, Masaki; Fujita, Masashi; Watanabe, Tetsuya; Iida, Osamu; Ishida, Yoshiteru; Nanto, Shinsuke; Uematsu, Masaaki

doi:10.1253/circj.cj-13-0464

Cited by 12 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous report identified only CTO as a risk factor for PSS after first‐generation SES implantation . Other studies showed that CTO was composed of thrombus, and 64% of late acquired PSS were in CTO lesions . CTO is a reasonable risk factor for PSS because stent deployment for CTO leads to ISA in the chronic phase .…”

Section: Discussionmentioning

confidence: 96%

“…In the present study, the rate of late acquired PSS after second‐generation DES implantation was 1.0%, in close agreement with the previous study. Recent research has shed light on the mechanism of PSS . In their optical coherence tomography study, Tada et al found that uncovered struts, malapposed struts, and red thrombus were more common in lesions with PSS than in lesions without PSS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors and Clinical Impacts of Peri‐Stent Contrast Staining After Second‐Generation Drug‐Eluting Stent Implantation

Tokuda

Yamawaki

Mori

et al. 2016

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Risk Factors and Clinical Impacts of Peri‐Stent Contrast Staining After Second‐Generation Drug‐Eluting Stent Implantation

Tokuda

Yamawaki

Mori

et al. 2016

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…CTO is one of the independent predictors of PSS, and the cumulative incidence of VLST is significantly higher in lesions with PSS after SES implantation . Some studies identified the mechanism that causes lesions with PSS . However, devising a treatment for lesions with PSS remains an unsolved problem, partly because PSS occurs at a low frequency.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Long‐Term Clinical Outcomes of Lesions Exhibiting Focal and Segmental Peri‐Stent Contrast Staining

Tokuda

Yamawaki

Takahara

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundPeri‐stent contrast staining (PSS) after metallic drug‐eluting stent deployment is associated with target lesion revascularization and very late stent thrombosis. However, the type of PSS that influences the clinical outcomes is unknown. Therefore, we aimed to reveal which PSS type was influencing clinical outcomes.Methods and ResultsThis study included 5580 de novo lesions of 4405 patients who were implanted with a first‐ or second‐generation drug‐eluting stent and who were evaluated using follow‐up angiography within 12 months after stent implantation. We compared the clinical outcomes of patients divided into focal PSS and segmental PSS groups for 6 years after stent implantation. Total PSS was observed in 97 lesions (2.2%), of which 42 and 55 lesions were focal and segmental PSS, respectively. Baseline characteristics were similar between groups, except for intraoperative chronic total occlusion (segmental PSS=47.3% versus focal PSS=11.9%, P=0.0001). The incidence of segmental PSS tended to be higher in patients with a first‐generation drug‐eluting stent (83.6% versus 16.4%, P=0.05). The cumulative incidence of stent thrombosis in the 6 years of segmental PSS group was significantly higher than that of the focal PSS group (13.9% versus 0%, P=0.04). The cumulative incidence of overall target lesion revascularization for restenosis, excluding target lesion revascularization procedures for stent thrombosis, was significantly higher in the segmental PSS group (38.0% versus 0%, P=0.01).ConclusionsThe incidence of segmental PSS tended to be higher in patients with a first‐generation drug‐eluting stent and appeared to be significantly associated with target lesion revascularization and stent thrombosis.

show abstract

“…29 It has been shown that the coronary segment with peri-stent contrast staining, which is known as a predictor of late stent thrombosis after DES implantation, frequently has yellow plaque (82%) and thrombus (64%). 30 According to the results of clinical trials with long-term follow-up to 5 years available in previous reports or at the website ClinicalTrial.gov, TLR at 1 and 5 years are 4.9% and 9.4% in Cypher-SES; 31,32 4.4% and 9.1% in Taxus paclitaxel-eluting stent (Taxus-PES); 33,34 5.9% and 7.5% in Endeavor-ZES; 35,36 and 3.4% and 8.9% in Xience-EES. 37 Therefore, the very late stent failure as shown by the yearly TLR between 1 and 5 years is 1.1%/year, 1.2%/year, 0.4%/year, and 1.4%/year in Cypher-SES, Taxus-PES, Endeavor-ZES, and Xience-EES, respectively, which appears to be lower in Endeavor-ZES than in other DES, although this is not the result of direct head-to-head comparison.…”

Section: Contributing Factors To Maximum Yellow Grade At Follow-upmentioning

confidence: 99%

Atherosclerotic Change at One Year After Implantation of Endeavor Zotarolimus-Eluting Stent vs. Everolimus-Eluting Stent

Akazawa

Matsuo

Ueda

et al. 2014

Circ J

View full text Add to dashboard Cite

Angioscopic Assessment of Peri-Stent Contrast Staining Following Drug-Eluting Stent Implantation

Cited by 12 publications

References 30 publications

Risk Factors and Clinical Impacts of Peri‐Stent Contrast Staining After Second‐Generation Drug‐Eluting Stent Implantation

Risk Factors and Clinical Impacts of Peri‐Stent Contrast Staining After Second‐Generation Drug‐Eluting Stent Implantation

Comparison of Long‐Term Clinical Outcomes of Lesions Exhibiting Focal and Segmental Peri‐Stent Contrast Staining

Atherosclerotic Change at One Year After Implantation of Endeavor Zotarolimus-Eluting Stent vs. Everolimus-Eluting Stent

Contact Info

Product

Resources

About